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Abstract
Background: Hemophilia gene therapy is a rapidly evolving therapeutic approach in 
which a number of programs are approaching clinical development completion.
Objective: The aim of this study was to evaluate knowledge and perceptions of a 
variety of health care practitioners and scientists about gene therapy for hemophilia.
Methods: This survey study was conducted February 1 to 18, 2019. Survey participants 
were members of the ISTH, European Hemophilia Consortium, European Hematology 
Association, or European Association for Hemophilia and Allied Disorders with valid 
email contacts. The online survey consisted of 36 questions covering demographic 
information, perceptions and knowledge of gene therapy for hemophilia, and educa-
tional preferences. Survey results were summarized using descriptive statistics.
Results: Of the 5117 survey recipients, 201 responded from 55 countries (4% re-
sponse rate). Most respondents (66%) were physicians, and 59% were physicians di-
rectly involved in the care of people with hemophilia. Among physician respondents 
directly involved in hemophilia care, 35% lacked the ability to explain the science of 
adeno-associated viral gene therapy for hemophilia, and 40% indicated limited ability 
or lack of comfort answering patient questions about gene therapy for hemophilia 
based on clinical trial results to date. Overall, 75% of survey respondents answered 
10 single-answer knowledge questions correctly, 13% incorrectly, and 12% were un-
sure of the correct answers.
Conclusions: This survey highlighted knowledge gaps and educational needs related 
to gene therapy for hemophilia and, along with other inputs, has informed the devel-
opment of “Gene Therapy in Hemophilia: An ISTH Education Initiative.”
K E Y W O R D S
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Essentials
• Hemophilia gene therapy is a rapidly evolving therapeutic approach with several phase 3 trials ongoing.
• This study explored knowledge and perceptions about hemophilia gene therapy among the health care team and scientists.
• The results highlighted knowledge gaps and educational needs related to gene therapy for hemophilia.
• These results informed an educational initiative to meet these needs for the hemophilia professional community.
1  | INTRODUCTION
Replacement therapy with plasma-derived clotting factors or recom-
binant clotting factor concentrates has long been the mainstay for 
the management of people with hemophilia; however, a limitation of 
this approach is the relatively short half-lives of the factor VIII (FVIII) 
and factor IX (FIX) replacement products.1 As a result, regular proph-
ylaxis with the goal of preventing bleeding episodes by maintaining 
trough factor levels above ~1% is associated with a high treatment 
burden (3-4 infusions per week for hemophilia A; 2-3 infusions 
per week for hemophilia B).2 Recent advances have expanded the 
therapeutic options for people with hemophilia, including extended 
half-life (EHL) products and nonreplacement factor therapies. These 
recent advances expand the treatment options for people with he-
mophilia, yet regular prophylaxis still imposes a significant treatment 
burden for both patients and health systems.
In contrast, gene therapy represents a potentially curative approach 
for people with hemophilia. As a monogenic disease, hemophilia is a 
logical target for gene therapy strategies, and minimal increases in clot-
ting factor levels may result in a change from a severe to mild pheno-
type, translating into reduced need for replacement therapy, reduced 
breakthrough bleeds, and improved quality of life. Strategies evaluated 
for FVIII and FIX gene transfer have included nonviral vectors, retro-
viral vectors, adenoviral vectors, lentiviral vectors, and adeno-asso-
ciated viral (AAV) vectors. Gene editing and cell-based therapies are 
additional investigational gene therapy strategies for hemophilia. Early 
phase clinical trials of AAV mediated liver-directed gene therapy for 
people with hemophilia A and people with hemophilia B have yielded 
promising results.3‒7 This is a rapidly evolving therapeutic approach, in 
which several programs are approaching clinical development comple-
tion. There is limited information about the knowledge, skills, and ex-
pertise of members of the hemophilia comprehensive care team related 
to gene therapy, an entirely new therapeutic paradigm. Such gene ther-
apy knowledge will enable health care providers to understand and be 
better prepared to integrate this novel therapy into their practice, and 
to be able to educate both their peers and patients on the benefits, lim-
itations, and potential risks of gene therapy. This study was conducted 
to evaluate knowledge and perceptions of a variety of health care prac-
titioners and scientists on gene therapy for hemophilia.
2  | MATERIALS AND METHODS
This was an international survey study conducted February 1 to 
18, 2019. Survey participants were all members of the ISTH, the 
European Haemophilia Consortium (EHC), the European Hematology 
Association, and the European Association for Haemophilia and 
Allied Disorders (EAHAD) with valid email contacts. The survey 
questionnaire was composed of 36 questions covering demographic 
information (9), perceptions about gene therapy for hemophilia (8), 
knowledge of gene therapy (10 single correct answer; 4 subjective), 
and educational preferences (5). A variety of question formats were 
included: single-answer check box, single answer from a drop-down 
menu, “select all that apply” or multiple responses allowed, 5-point 
Likert-type scale questions with descriptors of the point rating, open 
text response, and ranking. The ranking question format used a 
weighted approach in which overall rank was assigned by calculated 
score. Items ranked first by individual respondents are given higher 
value or weight than lower-ranked items; the sum of all weighted 
values is the score for a given item. Knowledge-based questions 
were presented only to those respondents who self-reported at 
least some understanding of the science of AAV-mediated liver-
directed gene therapy for hemophilia, as determined by response to 
a 5-point Likert-type scale question. Each knowledge-based ques-
tion included the answer option, “I’m not sure.” The questionnaire 
was accessed by participants online using the SurveyGizmo (https://
www.surve ygizmo.com/) platform. Survey results were summarized 
using descriptive statistics. Participation in the survey was volun-
tary and without compensation, and responses were confidential 
and deidentified for summarization and analysis.
3  | RESULTS
3.1 | Demographics
Of the 5117 survey recipients, 201 responded from 55 countries 
(4% response rate). Most respondents (66%) were physicians, and 
the majority (59%) were physicians directly involved in the care of 
people with hemophilia (Table 1). More than half of the participants 
practiced in academic medical centers, and 58% of respondents had 
≥15 years of experience in their current profession.
3.2 | Perceptions and knowledge related to 
hemophilia gene therapy
For 3 self-reported ability questions, an average of 58% of physi-
cians directly involved in the care of people with hemophilia rated 
their abilities as 4 or 5 on a 5-point Likert-type scale, with 1 being 
the lowest and 5 being the highest ability, compared with 46% 
of respondents not directly involved in the care of people with 
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hemophilia. When asked to rate their ability to explain the science 
behind AAV-mediated gene therapy for hemophilia to a colleague, 
65% of physicians directly involved in the care of people with he-
mophilia rated their abilities as 4 or 5 (Table 2). Among physician 
respondents involved in hemophilia care, 26% lacked the ability to 
explain AAV gene therapy, with an additional 9% lacking a clear 
understanding or had never heard of gene therapy. In addition, 40% 
of physicians involved in the care of people with hemophilia indi-
cated limited ability or lack of comfort answering patient questions 
about gene therapy for hemophilia based on clinical trial results to 
date, and 17% indicated limited or no understanding of how gene 
therapy may affect an individual’s current treatment for hemophilia.
TA B L E  1   Demographic characteristics 
of hemophilia gene therapy survey 
respondents Variable
Percentage of 
respondents
(n = 194)
Professional category
Physician 66
PhD/Researcher 13
Registered nurse, advanced practice registered nurse, or physician assistant 7
Technician, scientist, or technologist 5
Health business/medical administration professional 4
Other (including pharmacist; patient advocate; NGO; educator; health 
economist)
4
Student/Resident 1
Primary clinical focus
Bleeding disorders including hemophilia 39
Thrombosis and hemophilia 28
Hematology 11
Hematology/Oncology 8
Thrombosis/Clotting 7
Other nonclinical (bleeding disorders, FVIII, gene therapy, industry, product 
development, thrombosis and bleeding disorders, transfusion)
5
Internal medicine 1%
Other clinical (clinical chemistry) 1%
Role in the care of people with hemophiliaa 
Physician involved in direct patient care 59
Investigator in clinical trials of people with hemophilia 38
Patient education 27
Perform assays/assessments in a specialized coagulation laboratory 22
Basic research related to hemophilia but not related to patient care 20
Other (including nurse coordinator, nurse clinician, industry, administration, 
health care education, health economics and outcomes research, patient 
advocacy)
17
Practice setting
Academic medical center 54
Industry 13
Hemophilia treatment center (independent of an academic medical center) 11
Government hospital 9
Other (including nonprofit organization; patient organization; government 
research center)
7
Hemostasis center 3
Community-based hospital 2
Outpatient clinic/ambulatory setting 1
Abbreviations: FVIII, factor VIII; NGO, nongovernmental organization.
aRespondents could select all applicable responses. 
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Survey participants ranked 15 potential concerns or barriers 
related to gene therapy for hemophilia. Among physicians directly 
involved in the care of people with hemophilia, the top 3 concerns 
based on weighted ranking scores were long-term safety and moni-
toring, durability of expression/response, and challenges associated 
with use in specific populations (ie, children, those with inhibitors, 
neutralizing antibodies to AAV capsid proteins, etc) (Table 3).
Survey respondents who rated their ability to explain the science 
of AAV gene therapy for hemophilia to a colleague as 3, 4, or 5 on a 
5-point Likert-type scale were presented knowledge-based questions 
related to gene therapy for hemophilia. Of these 161 respondents, 124 
(77%) completed the knowledge-based questions. This subset of over-
all survey respondents was composed of a greater percentage of physi-
cians directly involved in the care of people with hemophilia compared 
to the overall group of survey respondents (64% vs 59%, respectively). 
Overall, 75% of respondents answered 10 single-answer knowledge 
questions correctly. Of physician respondents directly involved in the 
care of people with hemophilia, 78% answered the 10 questions cor-
rectly, 12% incorrectly, and 10% were unsure of the correct answers 
(Table 4). Among those respondents who self-reported as “expert” in 
TA B L E  2   Self-reported ability
Self-reported ability
Physicians directly 
involved in care 
of people with 
hemophilia (%)
Other 
respondents (%)
Ability to explain the science of AAV-mediated liver-directed gene therapy for hemophilia to a 
colleague (n = 177)
1—I’ve never heard of gene therapy 3 3
2—I do not have a clear understanding of how 
gene therapy works
6 6
3—I’ve learned about gene therapy, but still 
don’t think that I could explain it well to 
someone else
26 41
4—I know enough about gene therapy to feel 
comfortable educating colleagues, patients, 
and caregivers
54 40
5—I consider myself an expert 11 10
Ability to answer patient questions about gene therapy for hemophilia based on clinical trial 
results to date (n = 143)
1—I would not be able to answer questions 
about clinical trials of gene therapy for 
hemophilia
2 7
2—I have read about some of the studies, but 
would not feel very comfortable answering 
questions
11 24
3—I could answer a few basic questions about 
the studies
27 28
4—I feel comfortable answering questions 
about clinical trial results in gene therapy
50 30
5—I consider myself an expert 10 11
Ability to describe how gene therapy may impact an individual’s current treatment for 
hemophilia (n = 143)
1—I am not able to describe how gene therapy 
may impact an individual’s current treatment
1 9
2—I have a limited understanding of how 
gene therapy may impact current treatment 
practice for patients
16 22
3—I am able to explain how gene therapy 
may impact current treatment practice for 
patients
35 21
4—I am very comfortable with my ability to 
explain to my patients and colleagues how 
gene therapy may impact current treatment 
practice
38 35
5—I consider myself an expert 10 13
Abbreviation: AAV, adeno-associated viral.
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their ability to explain the science of AAV gene therapy for hemophilia, 
90% answered these 10 questions correctly, 6% incorrectly, and 4% 
were unsure of correct answers. Responses to 4 subjective knowledge 
questions are included in Table S1.
3.3 | Self-reported educational needs
All 131 respondents to a question about educational needs related 
to gene therapy identified at least 1 need, with an average of 5.6 
identified needs per respondent. Specific self-reported needs are 
summarized in Figure 1.
4  | DISCUSSION
This study was conducted to better understand perceptions and 
knowledge related to gene therapy as a treatment approach for peo-
ple with hemophilia among health care providers and scientists in 
the thrombosis and hemostasis professional community. The survey 
results indicated that many respondents are lacking in their abili-
ties to explain hemophilia gene therapy or answer patient questions 
about this emerging treatment approach for people with hemophilia. 
On knowledge questions, 25% of respondents overall, and 22% of 
physicians directly involved in the care of people with hemophilia in-
correctly answered or were not sure of correct answers. Survey re-
spondents recognized a range of educational needs related to gene 
therapy. These results expand on what has been previously reported 
about the knowledge level in the hemophilia care community about 
gene therapy. A different survey was conducted prior to the first 
World Federation of Hemophilia (WFH) Gene Therapy Round Table 
(convened in April 2018) to better understand the needs and knowl-
edge level of the hemophilia community.8 WFH survey respondents 
included 109 treating physicians from 76 countries. Of the physician 
treater respondents, 44% had “basic” or “intermediate” understand-
ing of gene therapy, with 12% indicating an “advanced” understand-
ing (specific survey questions were not reported).8 The authors noted 
that a recurrent theme throughout the roundtable discussions was the 
need for education at all levels. In a poster presentation, Hurst et al9 
reported results of a Continuing Medical Education–certified online 
clinical practice assessment that included 25 multiple-choice ques-
tions exploring knowledge, attitudes, and perspectives about gene 
therapy. Based on responses from hematology/oncology respond-
ents, the authors concluded that a majority of providers lack confi-
dence in their understanding of gene therapy for hemophilia A.9 The 
current survey study adds to these previous reports with additional 
specific knowledge-based questions, queries about self-reported 
abilities, ranking of perceived barriers/concerns, and respondent-
identified educational needs related to gene therapy for hemophilia.
Gene therapy represents a potentially transformative approach to 
hemophilia treatment that is distinct from existing therapies including 
EHL products and nonreplacement strategies. Notably, gene ther-
apy is potentially curative, producing long-term persistent outcomes, 
yet with the potential limitation of single treatment only, due to the 
immune response associated with vector exposure. These unique 
aspects of gene therapy highlight the importance of education to pro-
vide the bridge between evolving basic and clinical trial research and 
clinical practice. Our findings highlight gaps in knowledge related to 
gene therapy, including a need for better understanding of the funda-
mentals of gene therapy in general, and specifically how gene therapy 
is being developed as a treatment approach for hemophilia A and B. 
Our results suggest that it would be a mistake to assume that there 
is universal understanding of the basics about gene therapy; indeed, 
TA B L E  3   Potential concerns or barriers related to gene therapy 
for hemophilia (weighted ranking)
Physicians directly 
involved in care 
of people with 
hemophilia (n = 81)
Rank [score] Concern or barrier
Other 
respondents
(n = 49)
Rank [score]
1 [832] Long-term safety and 
monitoring
2 [454]
2 [815] Durability of expression/
response
1 [516]
3 [723] Challenges associated with 
use in specific populations 
(ie, children; those with 
inhibitors, neutralizing 
antibodies to AAV capsid, 
etc)
3 [417]a 
4 [674] Cost/reimbursement 3 [417]a 
5 [666] Elevation in liver enzymes; 
immune response to AAV 
capsid proteins
7 [371]
6 [622] Insertional mutagenesis 5 [407]
7 [597] Patient eligibility for clinical 
trials
11 [333]
8 [571] Limited scientific evidence 
will be available with which 
to make decisions about this 
treatment approach
10 [341]
9 [556] Current availability of safe 
and effective therapies
9 [347]
10 [547] Patient access to treatment 6 [386]
11 [530] Unknown unknowns 8 [352]
12 [510] Patient acceptance of gene 
therapy relative to their 
current treatment approach
15 [255]
13 [506] Risk for development of 
hepatocellular carcinoma
12 [328]
14 [474] Determining if it will be more 
advantageous for patients 
to wait for other emerging 
options
13 [318]
15 [449] Vector shedding 14 [274]
Abbreviation: AAV, adeno-associated viral.
aIdentical weighted scores. 
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these basics should be well understood before learning about specific 
clinical trials and related outcomes. Further, knowledge of current he-
mophilia gene therapy clinical trials is lacking, including the specific 
patient populations eligible for enrollment, efficacy and safety out-
comes, recent results, and ultimately the implications of results for 
clinical practice. Along with improved understanding of hemophilia 
gene therapy clinical trials and results, it will be important for the he-
mophilia care community to also be knowledgeable about outstanding 
questions and unknowns that require more data. The top barriers or 
concerns related to gene therapy for hemophilia identified by physician 
TA B L E  4   Answers to knowledge-
based question about gene therapy for 
hemophiliaQuestion [correct answer]
Answered 
correctly 
(%)
Answered 
incorrectly 
(%)
Answered 
“I’m not 
sure” (%)
Which of the following was a methodological 
challenge associated with early gene 
transfer studies for hemophilia A (relative to 
hemophilia B)? [size of the factor VIII protein 
(and therefore packaged transgene)]
84 12 4
60 31 9
Recent publications of success with gene 
therapy in people with hemophilia A and B 
have incorporated which of the following 
approaches? [adeno-associated viral vector 
gene transfer]
76 21 3
82 16 2
Recent publications have described 
successful gene therapy in hemophilia A 
and B. In these studies, was gene transfer 
accomplished in vivo or ex vivo? [in vivo]
81 13 6
91 5 4
Gene therapy for people with hemophilia has 
used a viral vector transfer approach that 
results in [Episomal persistence in the nucleus 
of target cells]
53 32 15
44 27 29
Successful gene therapy for people with 
hemophilia has affected which cell 
populations? [somatic cells]
87 4 9
73 5 22
In early-phase clinical trials using AAV-FVIII 
gene transfer in men with severe hemophilia 
A, what was the protein produced by this 
method? [B-domain deleted human FVIII]
67 16 17
64 14 22
In some studies of AAV-mediated FIX gene 
transfer in people with hemophilia B, a 
codon-optimized FIX Padua (FIX-R338L) 
transgene is being used. What is the rationale 
for this approach? [The high specific activity of 
this FIX variant means a lower dose can be used 
to achieve therapeutic expression and minimize 
risk of AAV capsid immune response]
85 2 13
76 8 16
Which statement describes safety outcomes 
from recent investigation of AAV5-gene 
therapy with expression of wild-type FIX in 
adults with hemophilia B? [The procedure has 
been generally well tolerated]
67 10 23
61 12 27
Which of the following has been a 
common adverse event noted in clinical 
trials of gene therapy for people with 
hemophilia? [Transient elevation of alanine 
aminotransferase (ALT) levels]
87 10 3
77 12 11
What is the anticipated treatment frequency 
with gene therapy for patients with 
hemophilia? [One-time infusion, with long-term 
follow-up]
89 5 6
78 13 9
Note: n = 79 physicians directly involved in care of people with hemophilia (rows shaded in 
green); n = 45 other respondents 9 (no row shading).
Abbreviations: AAV, adeno-associated viral; FIX, factor IX; FVIII, factor VIII.
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respondents directly involved in the care of people with hemophilia 
included long-term safety and monitoring, durability of expression/re-
sponse, and challenges associated with use in specific populations such 
as children or patients with preexisting immunity to AAV. Over 50% of 
survey respondents in the current study recognized their own need 
for education on clinical trial results for people with hemophilia, on 
patient eligibility for AAV-directed gene therapy for hemophilia, and 
safety considerations related to gene therapy for hemophilia.
In light of the rapid advances occurring with clinical trials of gene 
therapy for hemophilia, there is an important need for education so that 
the hemophilia care team is prepared for the potential integration of 
gene therapy into the treatment armamentarium for people with hemo-
philia. Fifty-nine percent of overall survey respondents indicated a need 
to learn how to educate patients about gene therapy for hemophilia. 
Evidence-based education can help to address misinformation and po-
tential preexisting biases so that people with hemophilia get fair and 
balanced information about gene therapy from health care providers.
Limitations of the current study include the short time frame for 
participation in the survey and sample size. Survey participants were 
not required to answer all questions (thus, the sample size is not con-
sistent across all questions), nor provide an explanation if they chose 
to skip a particular question. Survey participants may have a particular 
interest in gene therapy, representing selection bias that should be con-
sidered when interpreting the study results. The survey was available 
only in English, representing an additional limitation and potential for 
selection bias. For the above reasons, the results may not be generaliz-
able to all professional roles, practice settings, and geographic locations.
Providing education to address hemophilia gene therapy knowl-
edge gaps is not without challenges. There is a “culture of excellence” 
within the medical profession, in which learners may be embarrassed 
to admit deficiencies in knowledge or competence and may gravitate 
toward topics and material with which they are already familiar.10 
Limitations of time, distance/travel, and varied learning styles rep-
resent additional challenges in meeting individual learning needs. 
In the current study, respondents with little to no understanding 
of gene therapy as well as those who self-identified as “experts” 
recognized educational needs related to hemophilia gene therapy; 
therefore, a “one-size-fits-all” approach will not meet the range of 
educational needs. The results of this study have been used, among 
other inputs, for the development of a multiphased educational road 
map by the ISTH Gene Therapy for Hemophilia Steering Committee 
entitled “Gene Therapy in Hemophilia: An ISTH Education Initiative” 
(https://genet herapy.isth.org/). Incorporating a variety of educa-
tional formats and resources, this dynamic platform was designed 
F I G U R E  1   Self-identified educational needs related to gene therapy for hemophilia. For which topics related to gene therapy for 
hemophilia do you need education? AAV, adeno-associated viral; FIX, factor IX; FVIII, factor VIII
Safety considerations related to gene therapy for hemophilia
How to educate patients about gene therapy for hemophilia
Clinical trial results of gene therapy for people with hemophilia A
Clinical trial results of gene therapy for people with hemophilia B
Patient eligibility for AAV-directed gene therapy for hemophilia
Measurement of FVIII/FIX activity following gene therapy
Basic information about the history and science of gene therapy
Gene structure and expression of FVIII and FIX
Other
Physicians Directly Involved in Care of People with Hemophilia (n = 84) Other Respondents (n = 47)
Management of patients who are not candidates for AAV-directed gene
therapy
Lentiviral gene therapy and gene editing approaches for people with
hemophilia
Regulatory guidance related to gene therapy for hemophilia 71%47%
70%
62%
67%
45%
62%
60%
61%
49%
47%
57%
56%
32%
37%
51%
36%
36%
36%
34%
35%
40%
4%
1%
For which topics related to gene therapy for hemophilia do you need education?
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for the global hemophilia community to close existing knowledge 
gaps and to stay abreast of the evolving science and clinical advance-
ments in gene therapy in hemophilia.
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